Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval.

ABSTRACT: Cell replacement therapy is a promising therapeutic option for dry age-related macular degeneration (AMD). In this study, we outline our design for scalable manufacture with appropriate quality gates and present in vivo data for establishing preclinical safety and efficacy of an induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) product, thus laying the foundation for Phase 1/2a trial approval in India (ClinicalTrials.gov ID: NCT06394232; date of registration: 23^rd September 2024). Escalating doses of RPE cell suspension in immunocompromised animals demonstrated absence of tumor formation up to 9 months post-injection. Good Laboratory Practices (GLP) toxicology and tolerability studies in rabbits and non-human primates (NHP) respectively showed no majo

SUBMITTER: Soundararajan L 

PROVIDER: S-EPMC12009284 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature